Study on Interpretation of Quantitative Results of Prostate-specific Antigen Using Information Theory
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background : The prostate-specific antigen (PSA) is considered the most useful among tumor markers currently used. However, its quantitative results are interpreted only qualitatively for the diagnosis of prostate cancer. The recently introduced information theory enables the information of the quantitative results transformed into Shannon’s entropy (S) that represents uncertainties and then “1-S” representing diagnostic certainty. Methods : The 882 urological patients enrolled were categorized into 2 groups: a patient group comprising 233 patients with prostate cancer and a disease control group comprising 649 patients with benign prostate disease. The level of PSA in all the patients was tested and was found to be ≥2 ng/mL. The variables like PSA level and age were modeled on logistic regression analysis to predict the probability of prostate cancer and the diagnostic certainty. Results : The mean (SD) of PSA levels in the patient group and the disease control group were 44.5 ng/mL (37.62 ng/mL) and 5.7 ng/mL (3.70 ng/mL), respectively. The logistic regression model fitted well when the age variable was dichotomized at the age of 55 yr. The diagnostic certainty was lowest at a PSA level of 18.90 ng/mL in the <55-yr age group, and 15.45 ng/mL in the >55-yr age group. Conclusions : The diagnostic certainty (1-S) of whether to diagnose prostate cancer or not at a certain PSA level could be obtained using the information theory. The methodology used in this study may help interpret the results of other quantitative tests. (Korean J Lab Med 2010;30:357-63)
Abstract
Background : The prostate-specific antigen (PSA) is considered the most useful among tumor markers currently used. However, its quantitative results are interpreted only qualitatively for the diagnosis of prostate cancer. The recently introduced information theory enables the information of the quantitative results transformed into Shannon’s entropy (S) that represents uncertainties and then “1-S” representing diagnostic certainty. Methods : The 882 urological patients enrolled were categorized into 2 groups: a patient group comprising 233 patients with prostate cancer and a disease control group comprising 649 patients with benign prostate disease. The level of PSA in all the patients was tested and was found to be ≥2 ng/mL. The variables like PSA level and age were modeled on logistic regression analysis to predict the probability of prostate cancer and the diagnostic certainty. Results : The mean (SD) of PSA levels in the patient group and the disease control group were 44.5 ng/mL (37.62 ng/mL) and 5.7 ng/mL (3.70 ng/mL), respectively. The logistic regression model fitted well when the age variable was dichotomized at the age of 55 yr. The diagnostic certainty was lowest at a PSA level of 18.90 ng/mL in the <55-yr age group, and 15.45 ng/mL in the >55-yr age group. Conclusions : The diagnostic certainty (1-S) of whether to diagnose prostate cancer or not at a certain PSA level could be obtained using the information theory. The methodology used in this study may help interpret the results of other quantitative tests. (Korean J Lab Med 2010;30:357-63)
참고문헌 (24)
- Christenson RH, "Committee on Evidence Based Laboratory Medicine of the International Federation for Clinical Chemistry Laboratory Medicine. Evidence-based laboratory medicine - a guide for critical evaluation of in vitro laboratory testing", Ann Clin Biochem, 44, pp.111~130 (2007)
- Januzzi JL Jr, "The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study", Am J Cardiol, 95, pp.948~954 (2005)
- Vollmer RT, "Predictive probability of serum prostate-specific antigen for prostate cancer: an approach using Bayes rule", Am J Clin Pathol, 125, pp.336~342 (2006)
- Sampson HA, "Utility of food-specific IgE concentrations in predicting symptomatic food allergy", J Allergy Clin Immunol, 107, pp.891~896 (2001)
- Vollmer RT, "Entropy and information content of laboratory test results", Am J Clin Pathol, 127, pp.60~65 (2007)
- Guia¸su S, "Information theory with applications" (1977), McGraw-Hill
- Rudolph RA, "Information induction for predicting acute myocardial infarction", Clin Chem, 34, pp.2031~2038 (1988)
- Tanner MA, "Tools for statistical inference: methods for the exploration of posterior distributions and likelihood functions. 3rd ed" (1996), Springer
- Ben-Josef E, "Predicting the outcome of radio-therapy for prostate carcinoma: a model-building strategy", Cancer, 82, pp.1334~1342 (1998)
- Shannon CE, "The mathematical theory of communication" (1949), University of Illinois Press
- Altman DG, "Diagnostic tests 2: Predictive values", BMJ, 309, pp.102~ (1994)
- Smith RA, "Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening", CA Cancer J Clin, 59, pp.27~41 (2009)
- Barry MJ, "Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer", N Engl J Med, 344, pp.1373~1377 (2001)
- Catalona WJ, "Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng", mL and benign prostate examination. Enhancement of specificity with free PSA measurements, 1997, pp.277, 1452~1455
- Thompson IM, "Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter", N Engl J Med, 350, pp.2239~2246 (2004)
- Catalona WJ, "Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves", J Urol, 152, pp.2037~2042 (1994)
- Morgan TO, "Age-specific reference ranges for prostate-specific antigen in black men", N Engl J Med, 335, pp.304~310 (1996)
- Bernstein LH, "Medically significant concentrations of prostate-specific antigen in serum assessed", Clin Chem, 36, pp.515~518 (1990)
- Kochanska-Dziurowicz AA, "The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer", Br J Urol, 81, pp.834~838 (1998)
- Schroder FH, "Screening and prostate-cancer mortality in a randomized European study", N Engl J Med, 360, pp.1320~1328 (2009)
- Andriole GL, "Mortality results from a randomized prostate-cancer screening trial", N Engl J Med, 360, pp.1310~1319 (2009)
- Welch HG, "Prostate-specific antigen levels in the United States: implications of various definitions for abnormal", J Natl Cancer Inst, 97, pp.1132~1137 (2005)
- Etzioni R, "Studies of prostate-cancer mortality: caution advised", Lancet Oncol, 9, pp.407~409 (2008)
- Park SK, "Rising prostate cancer rates in South Korea", Prostate, 66, pp.1285~1291 (2006)